Investor Information
Overview
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.
Recent News & Filings
JUL 12, 2017
JUL 12, 2017
Precipio to Ring the Nasdaq Stock Market Opening Bell on July 12, 2017
JUL 11, 2017
Precipio, Inc. (Nasdaq: PRPO) to Ring The Nasdaq Stock Market Opening Bell
JUL 11, 2017
Precipio to Ring the Nasdaq Stock Market Opening Bell on July 12, 2017
JUL 05, 2017
JUL 03, 2017
4 - Statement of changes in beneficial ownership of securities
JUL 03, 2017
3 - Initial statement of beneficial ownership of securities
JUL 03, 2017
4 - Statement of changes in beneficial ownership of securities
JUL 03, 2017
SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
JUL 03, 2017
4 - Statement of changes in beneficial ownership of securities
INVESTOR RELATIONS
CORE IR
Scott Gordon
President
377 Oak Street
Garden City, NY 11530
TRANSFER AGENT
Wells Fargo Shareholder Services
1110 Centre Pointe Curve
Suite 101
St. Paul, MN 55120
AUDITORS
Marcum LLP
Michael K. Brooder
750 3rd Avenue, 11th Floor
New York, NY 10017
CORPORATE COUNSEL
Goodwin Procter LLP
Daniel A. Lang
The New York Times Building
620 Eighth Avenue
New York, NY 10018-1405
O: 212.459.7095
F: 646.558.4131
SUBSCRIBE TO IR NEWS AND FILING ALERTS
You can opt out at any time. We do not share or sell your info.
CONNECT WITH PRECIPIO:
